Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.84 USD | +1.66% | +1.66% | +44.88% |
May. 21 | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
May. 16 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 13.23M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.98
x | P/E ratio 2025 * |
-1.39
x | Employees | 9 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.57% |
Latest transcript on Inhibikase Therapeutics, Inc.
1 day | +1.66% | ||
1 week | +1.66% | ||
1 month | +25.17% | ||
3 months | -14.81% | ||
6 months | +96.27% | ||
Current year | +44.88% |
Managers | Title | Age | Since |
---|---|---|---|
Milton Werner
FOU | Founder | 61 | 08-08-31 |
C. Warren Olanow
CTO | Chief Tech/Sci/R&D Officer | - | 21-01-03 |
Dan Williams
AUD | Comptroller/Controller/Auditor | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Dennis Berman
BRD | Director/Board Member | 73 | 19-08-31 |
Paul Grint
BRD | Director/Board Member | 66 | 20-12-21 |
Milton Werner
FOU | Founder | 61 | 08-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.84 | +1.66% | 33,341 |
24-05-30 | 1.81 | -.--% | 14,250 |
24-05-29 | 1.81 | +2.84% | 19,775 |
24-05-28 | 1.76 | -2.76% | 20,639 |
24-05-24 | 1.81 | -1.09% | 33,059 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.88% | 13.23M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- IKT Stock